Table 3 Characteristics of the studies included in the systematic review AUC (adults)
Study | Design of study | Country of study | Duration of therapy (days) | Age of patients | No. of patients | AUC (mg・h/L) of patients | |
|---|---|---|---|---|---|---|---|
Thrombocytopenia | Non-thrombocytopenia | ||||||
NIAID 2018 [47] | Clinical Trial | Brazil, America | 7 | 18-65 | 10 (0/10) | ― | AUC24 Median: 232.9 |
Alffenaar 2010 [45] | Prospective pharmacokinetic study | Netherlands | Median: 56 | Median: 28 | 8 (0/8) | ― | AUC12 median:145.8 (AUC24 median:291.6) |
Alffenaar 2010 [65] | Prospective pharmacokinetic study | Netherlands | Median: 49 | Median: 28 | 12 (0/12) | ― | AUC12 Median: 123.8 (AUC24 median:247.6) |
Beer 2007 [46] | Prospective study | Austria | > 7 | Mean: 49.2 ± 19.5 | 5 (0/5) | ― | AUC12 Mean: 86.5 ± 44.5 (AUC24 mean:173) |
Bhalodi 2013 [48] | Prospective pharmacokinetic study | America | 2.5 | Mean: 42.2 ± 12.2 | 20 (0/20) | ― | AUC12 Mean: 119.8 ± 46.24 (AUC24 mean:239.6) |
Boak 2014 [49] | Prospective observational study | America | Mean: 22 | Mean: 54.0 (Thrombocytopenia patients) 60.5 (Non-thrombocytopenia patients) | 38 (10/28) | AUC24 Mean: 243 | AUC24 Mean: 213 |
Blackman 2021 [66] | prospective study | America | Mean: 4.6 ± 2.8 | 59.6: ±13.0 | 11(2/11) | AUC24: 345.8, 175.0a. | AUC24: 137.9, 233.6, 142.0, 144.0, 321.9, 191.6a, 142.6a, 126.3a, 328.3a |
Conte 2002 [50] | Prospective study | America | 2.5 | Mean: 30 ± 5 | 25 (0/25) | ― | AUC24 Mean: 204.2 |
Eslam 2014 [51] | Prospective study | Austria | ≧3 | 59-81 | 10 (0/10) | ― | AUC24 Mean: 164.5 ± 62.1 |
Gee 2001 [52] | Prospective study | United Kingdom | 2.5 | Mean: 29.6 | 6 (0/6) | ― | AUC12 Mean: 107.5 ± 40.6 (AUC24 mean:215) |
Luque 2014 [53] | Prospective pharmacokinetic study | Spain | > 3 | Mean: 51.9 ± 10.3 | 11 (0/11) | ― | AUC12 Median: 47.6 (AUC24 median:95.2) |
Myrianthefs 2006 [54] | Prospective study | Greece | ≧2 | Mean: 58.7 ± 17.3 | 14 (0/14) | ― | AUC12 Mean: 128.7 ± 83.9 (AUC24 mean:257.4) |
Pea 2012 [16] | Retrospective observational study | Italy | Median: 63 | Mean: 49.9 ± 15.2 | 35 (16/19) | AUC24 280.74 (50% probability) 343.02 (95% probability) | ― |
Swoboda 2010 [55] | Retrospective study | Germany | 2-4 | Mean: 57.2 ± 11.9 (septic patients on extended dialysis) 68.6 ± 4.2 (septic patients without dialysis) | 15 (0/15) | ― | AUC24 Mean:115.2 ± 70.6 (with dialysis) 123.5 ± 124.4 (without dialysis) |
Traunmüller 2010 [56] | Prospective study | Austria | ― | 60-67 | 3 (0/3) | ― | AUC24 Median: 229.4 |